VIDEO: NT-501 for macular telangiectasia nears PDUFA date

ByRichard Small

ByAnthony DeFino

Fact checked byChristine Klimanskis, ELS

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

KOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2025, Richard Small, CEO of Neurotech Pharmaceuticals, discusses the company’s macular telangiectasia therapy ahead of its upcoming Prescription Drug User Fee Act date.

NT-501 (revakinagene taroretcel) is an encapsulated cell therapy designed to continuously release therapeutic ciliary neurotrophic factor to the back of the eye.

The ocular implant received priority review designation from the FDA and has a PDUFA date of March 18, as Healio previously reported.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures: Small reports being CEO of Neurotech Pharmaceuticals.

Read more about

macular telangiectasia

retina

fda

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

• Facebook
• Twitter
• LinkedIn
• Email
• Print
• Comment